#Merck

Until now, Isentress (raltegravir) had been available only as a twice-daily drug.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.

The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir)

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Mondo Guerra shares how his life has changed since disclosing he has HIV on Project Runway in 2010.

Cutting through the hype and hyperbole.

The International AIDS Vaccine Initiative (IAVI) is a research and development nonprofit with partners in 25 countries.

In recent trials Harvoni, Viekira Pak and grazoprevir/elbasvir all cured high rates of hepatitis C among those coinfected with HIV.

Merck has filed a new drug application with the U.S. Food and Drug Administration (FDA) for approval of its single-tablet hepatitis C...

Highlights from the 50th Annual Meeting of the European Association for the Study of the Liver.